skip to content


Shire submits application for dry eye disease treatment

15 August 2017 09:15

Shire has submitted a Marketing Authorization Application (MAA) for lifitegrast in Europe.

If approved, lifitegrast would be the first and only treatment in a new class of drugs to address the signs and symptoms of dry eye disease in adults in Europe.

The disease is most commonly associated with eye dryness and overall eye discomfort, as well as stinging, burning, and fluctuating blurry vision.

Dry eye disease may significantly affect quality of life and may impact activities such as reading and using computers.

It is one of the most common conditions seen by ophthalmologists and eye care practitioners worldwide.

"This submission is another important milestone for lifitegrast and the millions of patients living with dry eye disease, which can impact a person's vision-related quality of life, affecting daily activities such as reading and using computers," said Howard Mayer, head of clinical development, R&D.

"Shire is committed to continued innovation in ophthalmics, where there are opportunities to address unmet need and improve the lives of patients."

At 9:15am: (LON:SHP) Shire PLC share price was +70.75p at 3863.75p

Story provided by

Related Company: SHP

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.